Trials / Completed
CompletedNCT02382276
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 405 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nalmefene hydrochloride |
Timeline
- Start date
- 2015-07-13
- Primary completion
- 2017-01-18
- Completion
- 2017-01-18
- First posted
- 2015-03-06
- Last updated
- 2020-07-20
- Results posted
- 2020-07-20
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02382276. Inclusion in this directory is not an endorsement.